{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:30:26Z","timestamp":1788499826013,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1193826"],"award-info":[{"award-number":["APP1193826"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1158469"],"award-info":[{"award-number":["APP1158469"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Society of Travel Medicine Research Awards"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Japanese encephalitis (JE) is endemic in Asia and the western Pacific. Vaccination is recommended for travellers to endemic regions, but the high cost of the vaccine is a major barrier to uptake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A quasi-experimental, pre-post intervention clinical trial without a control group was conducted to assess the immunogenicity and safety of intradermal (ID) JE vaccine. Healthy adults (18\u201345\u00a0years) received one dose of 0.1\u00a0mL (20% of standard dose) ID Imojev\u00ae (JE live attenuated chimeric vaccine, Sanofi-Aventis). Adverse events following immunization (AEFIs) were recorded 10\u00a0days post-vaccination. Blood samples were collected at baseline, 4 and 8\u00a0weeks post-vaccination. Neutralizing antibodies were measured using 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as PRNT50 titre \u226510. An in vitro study was also conducted to quantify the rate of decay of vaccine potency after reconstitution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 51 participants (72.6% females, median age 31\u00a0years), all non-reactive to JE virus at baseline were enrolled. Mild and moderate AEFIs were reported by 19.6% of participants; none required medical attention or interfered with normal daily activities. All participants seroconverted at 4\u00a0weeks (GMT 249.3; 95%CI:192.8\u2013322.5) and remained seropositive at 8 weeks (GMT 135.5; 95%CI:104.5\u2013175.6). Vaccine potency declined at a rate of 0.14 log plaque-forming units\/0.5\u00a0mL per hour.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In healthy adults, a single 0.1\u00a0mL ID dose of Imojev was safe and immunogenic, at least in the short term. Reconstituted vials of Imojev vaccine may not retain their potency after 6\u00a0hours. Fractional JE ID vaccination could be a cheaper yet effective alternative for short-term travellers. Further studies need to investigate the immune response in a wider age range of individuals and the long-term immunogenicity of fractional JE ID vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>ACTRN12621000024842.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jtm\/taac122","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T09:37:30Z","timestamp":1667036250000},"source":"Crossref","is-referenced-by-count":10,"title":["Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine"],"prefix":"10.1093","volume":"30","author":[{"given":"Luis","family":"Furuya-Kanamori","sequence":"first","affiliation":[{"name":"UQ Centre for Clinical Research , Faculty of Medicine, , Herston , Australia"},{"name":"The University of Queensland , Faculty of Medicine, , Herston , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Gyawali","sequence":"additional","affiliation":[{"name":"Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J","family":"Mills","sequence":"additional","affiliation":[{"name":"Dr Deb The Travel Doctor, Travel Medicine Alliance , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mills","sequence":"additional","affiliation":[{"name":"Dr Deb The Travel Doctor, Travel Medicine Alliance , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon E","family":"Hugo","sequence":"additional","affiliation":[{"name":"Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor J","family":"Devine","sequence":"additional","affiliation":[{"name":"Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen L","family":"Lau","sequence":"additional","affiliation":[{"name":"Dr Deb The Travel Doctor, Travel Medicine Alliance , Brisbane , Australia"},{"name":"School of Public Health , Faculty of Medicine, , Herston , Australia"},{"name":"The University of Queensland , Faculty of Medicine, , Herston , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"2023040512351235600_","article-title":"Japanese encephalitis virus (JEV)","author":"Australian Government - Department of Health and Aged Care","year":"2022"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"e51027","DOI":"10.7554\/eLife.51027","article-title":"Estimates of the global burden of Japanese encephalitis and the impact of vaccination from 2000-2015","volume":"9","author":"Quan","year":"2020","journal-title":"eLife"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/oxfordjournals.epirev.a036087","article-title":"The epidemiology of Japanese encephalitis: prospects for prevention","volume":"14","author":"Vaughn","year":"1992","journal-title":"Epidemiol Rev"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz064","article-title":"\u2018More than devastating\u2019 - patient experiences and neurological sequelae of Japanese encephalitis","volume":"26","author":"Turtle","year":"2019","journal-title":"J Travel Med"},{"key":"2023040512351235600_","first-page":"93","article-title":"Japanese encephalitis prevention and control: advances, challenges, and new initiatives","volume":"8","author":"Fischer","year":"2008","journal-title":"Emerg Infect"},{"key":"2023040512351235600_","volume-title":"CDC Yellow Book 2020: Health Information for International Travel","author":"Hills","year":"2019"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz037","article-title":"Japanese encephalitis vaccine for travelers: risk-benefit reconsidered","volume":"26","author":"Connor","year":"2019","journal-title":"J Travel Med"},{"key":"2023040512351235600_","article-title":"Japanese encephalitis","author":"Australian Government - Department of Health and Aged Care","year":"2018"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese encephalitis vaccine: recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.vaccine.2022.04.079","article-title":"Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: a systematic review and dose-response meta-analysis","volume":"40","author":"Islam","year":"2022","journal-title":"Vaccine"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa016","article-title":"Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety","volume":"27","author":"Kling","year":"2020","journal-title":"J Travel Med"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2020573","article-title":"Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia","volume":"18","author":"Islam","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa232","article-title":"Low uptake of Japanese encephalitis vaccination among Australian travellers","volume":"28","author":"Mills","year":"2021","journal-title":"J Travel Med"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw075","article-title":"Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet","volume":"24","author":"Lammert","year":"2016","journal-title":"J Travel Med"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab050","article-title":"Japanese encephalitis vaccine cost: a major reason to be vaccinated in Bali","volume":"28","author":"Wirawan","year":"2021","journal-title":"J Travel Med"},{"key":"2023040512351235600_","first-page":"365","article-title":"Yellow fever in Africa and the Americas, 2018","volume":"94","author":"World Health Organization","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1708-8305.2011.00540.x","article-title":"The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule \u2013 a case series of 420 travelers","volume":"18","author":"Mills","year":"2011","journal-title":"J Travel Med"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab188","article-title":"Long-term persistence of antibodies and boostability after rabies intradermal pre-exposure prophylaxis","volume":"29","author":"Mills","year":"2022","journal-title":"J Travel Med"},{"key":"2023040512351235600_","volume-title":"Rabies vaccines: WHO position paper \u2013 April 2018","author":"World Health Organization"},{"key":"2023040512351235600_","first-page":"345","article-title":"Yellow fever vaccine: WHO position on the use of fractional doses \u2013 June 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa181","article-title":"Could intradermal be an economical alternative route of administration for Japanese encephalitis vaccines?","volume":"28","author":"Furuya-Kanamori","year":"2021","journal-title":"J Travel Med"},{"key":"2023040512351235600_","volume-title":"Japanese encephalitis virus \u2013 medicine shortage information","author":"UNICEF Supply Division","year":"2021"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.4161\/21645515.2014.980197","article-title":"Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review","volume":"10","author":"Li","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.vaccine.2021.06.023","article-title":"Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: a systematic review and network meta-analysis","volume":"39","author":"Furuya-Kanamori","year":"2021","journal-title":"Vaccine"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.phrp.2014.08.003","article-title":"Comparison of four serological tests for detecting antibodies to Japanese encephalitis virus after vaccination in children","volume":"5","author":"Cha","year":"2014","journal-title":"Osong Public Health Res Perspect"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum Vaccin"},{"key":"2023040512351235600_","volume-title":"Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses","author":"World Health Organization","year":"2007"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.4161\/hv.29743","article-title":"A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea","volume":"10","author":"Kim","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/INF.0000000000000276","article-title":"Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety","volume":"33","author":"Feroldi","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4161\/hv.6.11.12854","article-title":"Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum Vaccin"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3201\/eid1511.091147","article-title":"Multicenter EuroTravNet\/GeoSentinel study of travel-related infectious diseases in Europe","volume":"15","author":"Gautret","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2019.12.059","article-title":"Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine in Karachi, Pakistan: a survey of caregiver and vaccinator acceptability","volume":"38","author":"Daly","year":"2020","journal-title":"Vaccine"},{"key":"2023040512351235600_","doi-asserted-by":"crossref","first-page":"e00395","DOI":"10.1016\/j.heliyon.2017.e00395","article-title":"Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan","volume":"3","author":"Yousafzai","year":"2017","journal-title":"Heliyon"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taac122\/47264719\/taac122.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/30\/2\/taac122\/49759427\/taac122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/30\/2\/taac122\/49759427\/taac122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T06:32:59Z","timestamp":1701239579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taac122\/6779982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,29]]},"published-print":{"date-parts":[[2023,4,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taac122","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2022,10,29]]},"article-number":"taac122"}}